From baseline, patients treated with AXS-12 had an 83% reduction in cataplexy attacks at the end of 5 weeks compared with a ...

For the next in our series of conditions GPs might rarely encounter, Neurology consultant Dr Clare Bolton provides an ...

The link between narcolepsy and cardiovascular disease (CVD) was strengthened by new evidence that the relationship applied ...

Among patients with narcolepsy, AXS-12 (reboxetine) vs placebo significantly reduced the frequency of cataplexy attacks.

本综述深入探讨了发作性睡病（Narcolepsy）的临床表现、治疗策略及未来方向，强调需超越经典五联征进行综合管理。 发作性睡病（Narcolepsy）是一种罕见的慢性神经学疾病，其特征性症状包括白天过度嗜睡（Excessive Daytime Sleepiness, EDS）、猝倒（Cataplexy）、夜间 ...

Nevertheless, the existing data do support such a theory: the disease is strongly associated with a T-cell receptor α gene variant, and 95% of patients with narcolepsy with cataplexy carry the ...

Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting ...

Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information ...

Cataplexy, or sudden muscle weakness that can resemble fainting, may be prompted by strong emotions. This symptom isn't serious and mostly occurs with narcolepsy type one — otherwise ...

The difference is that type 1 narcolepsy has cataplexy, the sudden loss of muscle tone, while type 2 does not. Despite the typical depiction of narcolepsy, it's not only excessive daytime sleepiness.

People with narcolepsy type 1 (with cataplexy) have low levels of orexin. Meanwhile, those with narcolepsy type 2 (without cataplexy) have normal levels of orexin. This suggests that type 2 is a ...